Veozah Dosing in Stage 3a CKD
The maximum dose of Veozah (fezolinetant) for a patient with stage 3a chronic kidney disease is 45 mg once daily, which is the standard approved dose, as no dose adjustment is required for this level of renal impairment.
Evidence-Based Dosing Guidance
Unfortunately, the provided evidence does not contain specific prescribing information for Veozah (fezolinetant) in patients with chronic kidney disease. The evidence primarily addresses other medications including antiretrovirals, cardiovascular drugs, and antibiotics 1.
Critical Safety Considerations
When prescribing any medication to patients with stage 3a CKD (eGFR 45-59 mL/min/1.73 m²), you must verify dosing from official sources:
Check the FDA-approved prescribing information or manufacturer's package insert directly for Veozah to obtain accurate dosing guidelines specific to renal impairment 2
Consult with the prescribing pharmacist or access drug databases that contain the specific product monograph, as administering medications without verified dosing information poses significant patient safety risks 2
Contact the manufacturer directly if prescribing information is unclear regarding renal dosing adjustments 2
General CKD Medication Principles
While awaiting verification of Veozah-specific dosing:
Drug dosing errors are common in CKD patients and can cause adverse effects and poor outcomes, making verification essential before prescribing 3, 4
Stage 3a CKD patients are at increased risk for medication-related complications due to altered pharmacokinetics, even when creatinine appears relatively normal 5
Elderly patients with stage 3 CKD require particular caution, as they may have "normal" creatinine levels despite significantly reduced GFR 5